The U.S. Food and Drug Administration announced over the weekend that thousands of tins of imported infant formula have been pulled from shelves due to a toxin that poses a health risk to infants.
In a notice issued Saturday, the FDA said the a2 Milk Company, based in Colorado, initiated a voluntary recall of three production batches of its a2 Platinum Premium USA formula. The product is marketed for children up to 12 months old.
According to the agency, laboratory tests detected cereulide, a toxin produced by certain strains of the Bacillus cereus bacterium. The FDA warned that the toxin is heat-stable, meaning it remains active even when the formula is mixed with hot water — a standard preparation method for some parents.
Infants who consume contaminated formula could become sick within as little as 30 minutes, the notice stated. Symptoms of cereulide poisoning typically include vomiting and diarrhea, which can lead to dehydration in vulnerable babies.
The recall underscores ongoing concerns about the safety of infant formula, a topic that has drawn heightened scrutiny since the 2022 Abbott Nutrition plant shutdown triggered nationwide shortages. In a related development, recent FDA test results showed most infant formula is free of heavy metals, but this incident highlights that other contaminants remain a risk.
Scope of the Recall
The FDA did not specify the exact number of tins affected, but described the recall as encompassing thousands of units. The a2 Milk Company said it is cooperating fully with regulators and has urged retailers to remove the affected batches from store shelves immediately.
Parents who have purchased the formula are advised to check the batch numbers listed on the FDA notice and return any affected product to the place of purchase for a full refund. The company also set up a hotline for consumer inquiries.
The recall is the latest in a series of food safety actions involving infant products. Earlier this year, Amazon hair growth serums were recalled over child safety violations, though in a different product category.
Regulatory Context
The FDA has been under pressure to strengthen oversight of imported infant formula, especially after the 2022 crisis exposed vulnerabilities in the supply chain. This recall may fuel calls for more rigorous testing protocols for foreign-made formula entering the U.S. market.
Meanwhile, the political landscape around infant nutrition remains charged. The recall comes as lawmakers debate tariffs on imported goods, which could affect the cost and availability of formula brands like a2 Platinum.
Health officials emphasize that parents should not hesitate to contact their pediatrician if they suspect their child has consumed the recalled formula and shows signs of illness. The FDA will continue to monitor the situation and may issue additional alerts if more batches are found to be contaminated.
